tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

REGN Stock Latest News

Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Asthma Treatment
Company AnnouncementsRegeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Asthma Treatment
33m ago
SNY
REGN
Regeneron and Sanofi’s Dupilumab Trial: A Potential Game-Changer for Ulcerative Colitis
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Trial: A Potential Game-Changer for Ulcerative Colitis
42m ago
SNY
REGN
Regeneron’s Promising Phase 3 Melanoma Study: A Potential Game-Changer?
PremiumCompany Announcements
Regeneron’s Promising Phase 3 Melanoma Study: A Potential Game-Changer?
47m ago
REGN
Regeneron’s Phase 3 Study on Odronextamab: A Potential Game-Changer for B-cell Lymphoma
PremiumCompany Announcements
Regeneron’s Phase 3 Study on Odronextamab: A Potential Game-Changer for B-cell Lymphoma
48m ago
REGN
Regeneron’s Promising Immunotherapy Study for Advanced Lung Cancer
PremiumCompany Announcements
Regeneron’s Promising Immunotherapy Study for Advanced Lung Cancer
1d ago
REGN
Regeneron and Sanofi’s Phase 3 Itepekimab Study: A Potential Game Changer for CRSwNP Treatment
PremiumCompany AnnouncementsRegeneron and Sanofi’s Phase 3 Itepekimab Study: A Potential Game Changer for CRSwNP Treatment
1d ago
SNY
REGN
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Asthma
Premium
Company Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Asthma
1d ago
SNY
REGN
Regeneron and Sanofi’s DUPIXENT® Study: A Boost for EoE Treatment Insights
Premium
Company Announcements
Regeneron and Sanofi’s DUPIXENT® Study: A Boost for EoE Treatment Insights
1d ago
SNY
REGN
Regeneron’s New ALS Study: A Potential Game-Changer for SOD1-ALS Treatment
PremiumCompany Announcements
Regeneron’s New ALS Study: A Potential Game-Changer for SOD1-ALS Treatment
1d ago
REGN
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Lichen Simplex Chronicus
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Lichen Simplex Chronicus
1d ago
SNY
REGN
Regeneron’s Cemiplimab Study: A Potential Game-Changer for Skin Cancer Treatment
PremiumCompany Announcements
Regeneron’s Cemiplimab Study: A Potential Game-Changer for Skin Cancer Treatment
1d ago
REGN
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for CRSwNP
PremiumCompany Announcements
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for CRSwNP
1d ago
SNY
REGN
Regeneron and Sanofi’s Promising Phase 3 Study on Dupilumab for LSC
PremiumCompany AnnouncementsRegeneron and Sanofi’s Promising Phase 3 Study on Dupilumab for LSC
1d ago
SNY
REGN
Regeneron’s Latest Clinical Study: A New Hope for Advanced NSCLC Treatment
Premium
Company Announcements
Regeneron’s Latest Clinical Study: A New Hope for Advanced NSCLC Treatment
3d ago
REGN
Regeneron price target raised to $640 from $600 at BMO Capital
Premium
The Fly
Regeneron price target raised to $640 from $600 at BMO Capital
4d ago
REGN
Regeneron price target raised to $815 from $810 at Guggenheim
PremiumThe Fly
Regeneron price target raised to $815 from $810 at Guggenheim
4d ago
REGN
Regeneron price target raised to $543 from $504 at BofA
PremiumThe Fly
Regeneron price target raised to $543 from $504 at BofA
4d ago
REGN
Positive Indicators and Strategic Investments Support Buy Rating for Regeneron
PremiumRatings
Positive Indicators and Strategic Investments Support Buy Rating for Regeneron
4d ago
REGN
Regeneron price target raised to $761 from $754 at Morgan Stanley
PremiumThe Fly
Regeneron price target raised to $761 from $754 at Morgan Stanley
5d ago
REGN
Regeneron price target raised to $753 from $750 at Bernstein
PremiumThe FlyRegeneron price target raised to $753 from $750 at Bernstein
5d ago
REGN
Cautious Outlook on Regeneron Despite Strong Performance: Sell Rating Due to Potential Eylea Erosion and Medicare Risks
Premium
Ratings
Cautious Outlook on Regeneron Despite Strong Performance: Sell Rating Due to Potential Eylea Erosion and Medicare Risks
5d ago
REGN
Regeneron Pharmaceuticals Reports Strong Q2 2025 Results
Premium
Company Announcements
Regeneron Pharmaceuticals Reports Strong Q2 2025 Results
7d ago
REGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >